Extracellular matrix biosynthesis pathway (ECM biosynthesis)

The extracellular matrix (ECM) biosynthesis pathway represents a coordinated network of intracellular and extracellular events responsible for the production, modification, and assembly of the structural scaffold of tissues, including collagens, elastin, and proteoglycans (Reactome, R-HSA-1474244). These pathways are essential for maintaining organ architecture, providing mechanical strength, and regulating cell behavior through biochemical and biomechanical signaling (NCBI, PMC7071644). In healthy states, ECM production is tightly balanced with degradation; however, its dysregulation is a hallmark of chronic fibrotic diseases and cancer (Nature Reviews Molecular Cell Biology, 2014). In fibrosis, excessive deposition of ECM components leads to progressive organ scarring and failure, while in the tumor microenvironment, aberrant ECM remodeling facilitates cancer cell invasion and metastasis (PubMed, 28234314). Therapeutic strategies targeting these pathways often focus on inhibiting master regulators like Transforming Growth Factor-beta (TGF-β) or downstream enzymes such as lysyl oxidase (LOX) to prevent pathological matrix accumulation (Journal of Clinical Investigation, 2017). Clinical agents like Pirfenidone and Nintedanib are currently used to slow the progression of fibrotic conditions by modulating these biosynthetic and signaling cascades (FDA, 2014).

Other names

Extracellular matrix organizationECM productionCollagen biosynthesisMatrix assemblyProteoglycan biosynthesis

Modulation of TGF-beta signaling, inhibition of receptor tyrosine kinases (VEGFR, FGFR, PDGFR), inhibition of lysyl oxidase-like 2 (LOXL2), and regulation of pro-collagen processing and cross-linking.